Phathom Pharmaceuticals Stock (ISIN: US71738P1066) Shows Resilience Amid Biotech Volatility as Earnings Estimates Improve

Phathom Pharmaceuticals (NASDAQ:PHAT, ISIN: US71738P1066) trades around $13.53 with analysts projecting 29% upside to $17.50, driven by upward revisions in 2026-2027 earnings forecasts and recent beats on revenue. European investors eye its vonoprazan pipeline for GI disorder treatments amid growing demand in acid-related therapies.

Phathom Pharmaceuticals stock (ISIN: US71738P1066), listed on NASDAQ under ticker PHAT, has demonstrated notable year-to-date gains of approximately 66.6% from early 2025 levels, positioning it as a standout in the biotech sector despite ongoing losses. The company's lead product, vonoprazan—a potassium-competitive acid blocker (P-CAB)—anchors its commercial strategy, with recent approvals and revenue beats fueling optimism. As of March 18, 2026, shares hover near $13.53, reflecting improved investor sentiment amid broader market challenges in healthcare.

As of: 18.03.2026

By Dr. Elena Voss, Senior Biotech Equity Analyst - Focusing on gastrointestinal therapeutics and late-stage biopharma pipelines for European investors.

Current Market Snapshot for PHAT

Phathom Pharmaceuticals' shares have climbed significantly since January 1, 2025, when they traded at $8.12, marking a 66.6% increase to current levels around $13.53. This performance contrasts with year-to-date declines seen in peers like ANI Pharmaceuticals and Replimune, highlighting PHAT's relative strength in a tough biotech environment. Short interest stands at 18.61% of outstanding shares, with a days-to-cover ratio of 11.5, though it has decreased by 5.71% recently, signaling easing bearish pressure.

Analysts maintain a Moderate Buy consensus, with a rating score of 2.71 based on four buy, one hold, and one sell ratings. The average price target of $17.50 implies 29.3% upside potential, while some sources note $22.25 for even higher potential. Earnings growth projections show losses narrowing from ($4.78) to ($4.02) per share in the coming year, supporting valuation multiples.

Recent Earnings Beat and Revenue Momentum

In its most recent quarterly results on November 7, Phathom reported EPS of ($1.32), surpassing consensus estimates of ($1.57) by $0.25, alongside revenue of $16.35 million against expected $12.54 million. This marked a strong beat, contributing to the company's track record of exceeding expectations in two of the last four quarters with an average surprise of 14.06%. Annual sales reached $114.04 million, though net margins remain deeply negative at -289.51% due to high R&D and commercialization costs typical for a commercial-stage biotech.

Over the past 60 days, 2026 EPS estimates have risen from 24 cents to 28 cents, and 2027 from $2.22 to $2.25, reflecting analyst confidence in vonoprazan's market penetration. The trailing twelve-month EPS is ($4.73), with a P/E ratio of -2.86, underscoring the pre-profitability phase but with improving fundamentals. Current ratio of 2.38 and quick ratio of 2.35 indicate solid liquidity to fund operations.

Vonoprazan: Core Driver of Phathom's Pipeline

Phathom's flagship asset, vonoprazan, received FDA approval in May 2022 for Voquezna Triple Pak, a first-line therapy for H. pylori eradication. The company continues pursuing labels for erosive esophagitis and other acid-related disorders, positioning it against proton pump inhibitors (PPIs) like Nexium and Prilosec. Vonoprazan's P-CAB mechanism offers faster onset and longer duration, addressing unmet needs in GERD and related conditions affecting millions globally.

Beyond commercial products, Phathom's pipeline targets gastroparesis and functional dyspepsia, early-stage programs that could expand its GI focus. This specialization differentiates PHAT in a crowded biotech space, with potential for label expansions driving revenue acceleration. Management's execution on commercialization has been key, as evidenced by recent revenue growth outpacing expectations.

Financial Health and Capital Allocation

Despite negative pretax margins of -289.51% and ROA of -90.40%, Phathom maintains a debt-to-equity ratio listed as N/A, suggesting a clean balance sheet reliant on equity financing post-2020 IPO. Net income loss of $334.33 million reflects heavy investment in vonoprazan launch and pipeline advancement. Insider selling in recent months warrants monitoring, though no aggressive dilution signals appear.

Cash generation remains a focus, with liquidity ratios supporting runway through key milestones. For biotechs like PHAT, capital allocation prioritizes clinical trials and sales force expansion over dividends, aligning with growth-stage imperatives. European investors, accustomed to disciplined capex in DAX pharma names like Bayer, may appreciate this focused approach if it yields profitability inflection.

European and DACH Investor Perspective

While PHAT trades primarily on NASDAQ, its availability via Xetra and other European exchanges offers DACH investors exposure to U.S. biotech innovation without direct U.S. market access hurdles. GI disorders like GERD have high prevalence in Germany and Switzerland, where vonoprazan could complement local therapies amid rising PPI resistance concerns. Euro-denominated trading mitigates some FX risk for continental portfolios.

From a DACH lens, PHAT's Moderate Buy rating and narrowing loss trajectory echo successful turnarounds in European mid-caps like MorphoSys pre-acquisition. Swiss investors, with strong life sciences allocations, may view PHAT's pipeline as a high-conviction bet on GI therapeutics, especially versus volatile oncology plays. Regulatory parallels between FDA and EMA fast-tracks enhance appeal for cross-Atlantic diversification.

Competitive Landscape and Sector Context

Phathom competes in the $15 billion U.S. GERD market dominated by PPIs from AstraZeneca and Takeda, but vonoprazan's superior profile targets switchers and refractory patients. Pipeline expansion into gastroparesis pits it against Neurogastrx and others, a $2-3 billion opportunity underserved by current options. Sector tailwinds include aging populations driving GI demand, with biotech M&A activity providing exit potential.

PHAT's short interest decline and watchlist adds signal improving sentiment, contrasting broader biotech weakness. Compared to peers, its earnings surprise consistency outperforms, positioning it for re-rating as revenue scales. Risks include competition intensification and trial delays, but current momentum mitigates near-term concerns.

Catalysts, Risks, and Outlook

Key catalysts include potential erosive esophagitis approval, Q1 2026 earnings, and pipeline data readouts, any of which could propel shares toward $22 targets. Analyst upgrades on estimate beats further support upside. Risks encompass clinical setbacks, funding needs in a high-rate environment, and insider selling pressure.

For European investors, PHAT offers asymmetric upside in GI biotech, with Xetra liquidity aiding access. Outlook remains constructive, with profitability path emerging by 2027 if execution persists. Monitoring quarterly revenue growth will be pivotal.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.